

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

APC anti-human CD3

RRID:AB_314048

Type: Antibody

Proper Citation

BioLegend Cat# 300312, RRID:AB_314048

Antibody Information

URL: http://antibodyregistry.org/AB_314048

Proper Citation: BioLegend Cat# 300312, RRID:AB_314048

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone HIT3a

Antibody ID: AB_314048

Vendor: BioLegend

Catalog Number: 300312

Alternative Catalog Numbers: 300311

Record Creation Time: 20250820T053235+0000

Record Last Update: 20250820T214905+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD3.

No alerts have been found for APC anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Yu S, et al. (2026) A CLOCK-targeting lncRNA induces trained immunity against tuberculosis. *Cell host & microbe*, 34(1), 68.

Wang X, et al. (2025) An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis. *Cell*, 188(16), 4225.

Wang D, et al. (2025) Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission. *Med (New York, N.Y.)*, 100749.

Zhang T, et al. (2025) Humanized mouse model reveals T cell ANXA2 as a potential therapeutic target in ischemic stroke. *iScience*, 28(5), 112302.

Stahl D, et al. (2025) CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma. *Cancer cell*, 43(8), 1476.

Gu C, et al. (2025) An innovative engineered IL-10 monomer strengthens T cell-mediated anti-tumor responses through anti-PD-1 cis-delivery. *Cell reports. Medicine*, 102515.

Cui L, et al. (2024) Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer. *Cancer research*.

Wang H, et al. (2024) Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma. *Cell reports*, 43(12), 115015.

Guimarães SJA, et al. (2024) Human papillomavirus infection affects the immune microenvironment and antigen presentation in penile cancer. *Frontiers in oncology*, 14, 1463445.

Nunoya JI, et al. (2024) Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-Stimulatory Signal Domain Exhibits Exhaustion-Resistant Properties. *International journal of molecular sciences*, 25(16).

Wang X, et al. (2024) Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. *Cell*, 187(18), 4890.

Luo Y, et al. (2024) Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. *Cell*, 187(18), 4905.

Ren X, et al. (2022) Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model. *STAR protocols*, 3(4), 101818.

Ye L, et al. (2022) A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. *Cell metabolism*, 34(4), 595.

Yu B, et al. (2022) Engineered cell entry links receptor biology with single-cell genomics. *Cell*, 185(26), 4904.

Morton JJ, et al. (2021) Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. *Molecular cancer research : MCR*, 19(2), 346.

Hara T, et al. (2021) Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. *Cancer cell*, 39(6), 779.

Dong MB, et al. (2019) Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. *Cell*, 178(5), 1189.